Abstract
Medullary thyroid carcinoma (MTC) responds very poorly to chemotherapy. Mutations in the RET gene are critical for MTC pathogenesis. RET therefore represents a rational target for the development of novel MTC therapies. The accumulation of evidence from laboratory studies strongly suggests that PP1 inhibitor is a cytostatic agent for cells expressing RET oncoproteins. PP1 functions as a potent and selective inhibitor of RET oncoprotein phosphorylation, promoting its proteasomal degradation.
Original language | English |
---|---|
Pages (from-to) | 550-552 |
Number of pages | 3 |
Journal | Tumori |
Volume | 89 |
Issue number | 5 |
Publication status | Published - Sep 2003 |
Keywords
- Medullary thyroid cancer pathogenesis
- MEN 2A
- MEN 2B
- PP1 inhibitor
- RET oncoproteins
ASJC Scopus subject areas
- Cancer Research